Brief: Sorrento Therapeutics Announces FDA Clearance Of Its Ind Application Of Next Generation Ohsv Oncolytic Virus STI-1386
20/12/2021 14:10
Dec 20 (Reuters) - Sorrento Therapeutics Inc SRNE.O :
* SORRENTO THERAPEUTICS ANNOUNCES FDA CLEARANCE OF ITS IND
APPLICATION OF NEXT GENERATION OHSV ONCOLYTIC VIRUS STI-1386 FOR
PATIENTS WITH RELAPSED AND REFRACTORY SOLID TUMORS
Source text for Eikon: ID:nGNX9dyTVx
Further company coverage: SRNE.O
Recent news on Sorrento Therapeutics
See all newsBrief: Scilex Holding Says US Bankruptcy Court Extended Lockup Period On Shares Of Scilex Stock
Company's PO box allows it to file for bankruptcy in Texas, judge rules
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute (updated)
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute
Brief: Sorrento Therapeutics Reduced U.S. Headcount From 215 To 128 on Sept. 20